Oramed Pharmaceuticals, Inc. (OQ:ORMP)

Business Focus: Biotechnology & Medical Research

Mar 19, 2024 09:00 am ET

Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Inno

Scilex Holding Company (Nasdaq: SCLX, “Scilex”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it...

Feb 20, 2024 07:30 am ET

Oramed Letter to Shareholders

Initiating Phase 3 oral insulin trial in the United States under a new protocol JV with Chinese Partner, HTITScilex Senior Secured NotePeriTech Asset Purchase & Strategic Out-licensing NEW YORK, Feb. 20, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its President and Chief Executive Officer, Nadav Kidron.

Sep 22, 2023 11:38 am ET

Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Co

SAN DIEGO, Sept. 22, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento" or "Company"), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, announced the consummation on September 21, 2023, of the previously announced sale to Scilex Holding Company (Nasdaq: SCLX, "Scilex") of certain securities that Sorrento held in Scilex.

Sep 22, 2023 09:31 am ET

Thinking about buying stock in MicroAlgo, Oramed Pharmaceuticals, Limbach Holdings, Niu Technologies, or Applied Molecular Transport?

NEW YORK, Sept. 22, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MLGO, ORMP, LMB, NIU, and AMTI.

Sep 21, 2023 06:11 pm ET

Oramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding Company

18-month loan with interest rate of SOFR plus 8.5% Oramed receives warrants to purchase up to 17 million shares of Scilex common stock The Senior Secured Note with Scilex replaces Oramed's previously announced Stock Purchase Agreement and DIP Term Loan with Sorrento TherapeuticsNEW YORK, Sept. 21, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE:ORMP) today announced that on September 21, 2023, Oramed and Scilex Holding Company ("Scilex") entered into a Securities Purchase Agreement pursuant to which Scilex issued a Senior Secured Promissory Note (the "Note") to Oramed.

Sep 21, 2023 04:05 pm ET

Scilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc.

Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced...

Sep 13, 2023 09:00 am ET

Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Dec

Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”), an innovative revenue-generating company focused on acquiring, developing and commercializing...

Jun 20, 2023 07:55 am ET

Oramed to Present at the 83rd American Diabetes Association Conference

NEW YORK, June 20, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), announced today that it has been selected to present an oral abstract presentation at the American Diabetes Association's 83rd Scientific Sessions, taking place between June 23-26, 2023 in San Diego, California.

May 18, 2023 07:55 am ET

Oramed to Present at Novel Therapies for Type 2 Diabetes & Obesity Summit

NEW YORK, May 18, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), announced today that Chief Scientific Officer Dr. Miriam Kidron will deliver an in-person presentation at the Novel Therapies for Type 2 Diabetes & Obesity Summit in Boston, MA, on May 31, 2023. The presentation will include an overview of Oramed's oral delivery technology as well as insights from the Company's recent Phase 3 oral insulin clinical trials.

May 15, 2023 09:05 am ET

Oramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in China

Oramed has completed an analysis of its U.S.-based Phase 3 oral insulin trial with significant lowering of A1C levels seen in patient subgroups

May 04, 2023 12:05 pm ET

Thinking about buying stock in Zillow, Li Auto, Endeavour Silver, Protalix Biotherapeutics, or Oramed Pharmaceuticals?

NEW YORK, May 4, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for Z, LI, EXK, PLX, and ORMP.

May 01, 2023 04:45 pm ET

Oramed Appoints Ben Shapiro to its Board of Directors

NEW YORK, May 1, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) ("Oramed" or the "Company") (www.oramed.com) announced today the appointment of Mr. Benjamin Shapiro to its Board of Directors effective May 1, 2023. The Board determined that Mr. Shapiro qualifies as an independent director under the listing rules of the Nasdaq Capital Market.

Feb 09, 2023 06:55 am ET

Oramed Pharmaceuticals Issues Shareholder Update

NEW YORK, Feb. 9, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), announced today that it continues to conduct a comprehensive analysis of the data from its discontinued Phase 3 oral insulin trials. In addition, management and the Board of Directors are examining the Company's existing pipeline and conducting a comprehensive review of strategic alternatives focused on enhancing shareholder value.

Jan 11, 2023 07:00 pm ET

Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes

NEW YORK, Jan. 11, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today top-line results from its Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trial (ORA-D-013-1) comparing the efficacy of ORMD-0801 to placebo in patients with Type 2 Diabetes (T2D) at 26 weeks. ORA-D-013-1 enrolled 710 patients with T2D and inadequate glycemic control on two or three oral glucose-lowering agents.

Jan 04, 2023 06:55 am ET

Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes

NEW YORK, Jan. 4, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that the United States Patent and Trademark Office has granted the Company a patent titled "Methods and Compositions for Treating Diabetes." The patent serves as an extension to a patent previously granted in May 2022 and addresses methods and compositions for treating diabetes mellitus through oral pharmaceutical compositions comprising insulin in combination with

Dec 21, 2022 07:25 am ET

Oramed Letter to Shareholders

Topline Pivotal Phase 3 Oral Insulin Data Expected Mid-January 2023Phase 2 NASH Trial Achieved Primary and Secondary EndpointsDefinitive Deal Signed to Commercialize Oral Insulin in South Korea $160 Million in Cash and Investments (as of September 30, 2022)NEW YORK, Dec. 21, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidron.

Nov 29, 2022 07:40 am ET

Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism

NEW YORK, Nov. 29, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that Diabetes, Obesity, and Metabolism, has published an original article titled: "Oral Insulin (ORMD-0801) in Type 2 Diabetes Mellitus: Dose-Finding 12-Week Randomized Placebo-Controlled Study," authored by Roy Eldor, MD PhD, Bruce H. Francis, MD, Alexander Fleming, MD, Joel Neutel, MD, Kenneth Homer, MS, Miriam Kidron, PhD, and Julio Rosenstock, MD.

Nov 17, 2022 11:25 am ET

Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH

Achieved primary endpoint of safety and tolerability in participants with Type 2 diabetes with NASH.Oral insulin candidate demonstrates consistent trends across key secondary endpoints with reduction of liver fat, liver stiffness and lipids.Key opinion leaders' discussion highlights new data and is available on demand.NEW YORK, Nov. 17, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced additional positive data from its Phase 2 double-blind, fully ran

Nov 14, 2022 06:55 am ET

Oramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea

Medicox to Distribute Oramed's Oral Insulin in South Korea, if approvedOramed to Receive Up to $18 Million in Developmental MilestonesOramed to Receive up to 15% Royalties on Gross SalesLarge Market Potential: 1 in 7 Koreans Over Age 30 Has DiabetesNEW YORK , Nov. 14, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced it has signed an exclusive commercial distribution agreement for the Republic of Korea (formerly South Korea) with Medicox Co.

Nov 10, 2022 03:30 pm ET

Oramed Reports Third Quarter 2022 Financial Results

NEW YORK, Nov. 10, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. ("Oramed" or the "Company") (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today reported its financial results for the quarter ended September 30, 2022.

Nov 09, 2022 07:40 am ET

Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH

Webinar scheduled for Thursday, November 17, 2022, at 11:00 a.m. ESTFeaturing key opinion leader discussion on current treatment landscapeNEW YORK, Nov. 9, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that it will host a data presentation on newly released safety and efficacy data from the Phase 2 trial of its oral insulin candidate (ORMD-0801) to reduce liver fat content in Type 2 Diabetes ("T2D") patients with non-alcoholic st

Oct 07, 2022 08:40 am ET

Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine

Primary and secondary endpoints of safety and immunogenicity met Oral vaccine elicited a potentially protective IgG response with significant seroconversion from baseline Trial shows proof of concept for oral delivery of vaccines using Oravax technology NEW YORK, Oct. 7, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that its subsidiary, Oravax Medical Inc., reported positive preliminary data from its Phase 1 trial of an oral Covi

Sep 13, 2022 08:40 am ET

Oramed Reports Positive Top-Line Results from Phase 2 NASH Trial with its ORMD-0801, Oral Insulin Candidate

Primary endpoint met: ORMD-0801 was safe and well toleratedSecondary endpoint met: ORMD-0801 showed clinically meaningful reduction of liver fat from baseline at 12 weeksStrong evidence for treatment of NASH using Oramed's oral insulinNEW YORK, Sept. 13, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today positive Phase 2 results from its double-blind, fully randomized, placebo-controlled, multicenter trial to assess the safety and eff

Apr 05, 2022 08:25 am ET

Oramed Granted NASH Patent in Europe

NEW YORK, April 5, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that the European Patent Office has granted the Company the patent titled "Methods and Compositions for Treating NAFLD, Hepatic Steatosis, and Sequelae Thereof." This patent was previously granted to Oramed in the U.S. and is pending in several other major markets.

Feb 02, 2022 08:31 am ET

Thinking about buying stock in Oramed Pharmaceuticals, Allegheny Technologies, Evercore, Vertex Energy, or AST SpaceMobile?

NEW YORK, Feb. 2, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ORMP, ATI, EVR, VTNR, and ASTS.

Nov 24, 2021 08:31 am ET

Thinking about buying stock in Ocuphire Pharma, Seelos Therapeutics, Anavex Life Sciences, Leap Therapeutics, or Oramed Pharmaceuticals?

NEW YORK, Nov. 24, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OCUP, SEEL, AVXL, LPTX, and ORMP.

Nov 18, 2021 06:40 am ET

Oramed Subsidiary Oravax Medical and Genomma Lab Internacional Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America

NEW YORK and MEXICO CITY, Nov. 18, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, and Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) (www.genommalab.com/en/), a leading pharmaceutical and personal care product company in Latin America with an expanding international presence, today announced the formation of a 50/50 joint venture between Genomma Lab and Oramed's majority-owned subsidiary Oravax Medical Inc. (www.ora-vax.com) to develop and c

Aug 18, 2021 09:31 am ET

Thinking about buying stock in Aprea Therapeutics, Commscope, RealReal, Oramed Pharmaceuticals, or Verb Technology?

NEW YORK, Aug. 18, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APRE, COMM, REAL, ORMP, and VERB.

Aug 10, 2021 08:30 am ET

Thinking about buying stock in Arcturus Therapeutics, IMV Inc, Fisker, Oramed Pharmaceuticals, or Summit Wireless?

NEW YORK, Aug. 10, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ARCT, IMV, FSR, ORMP, and WISA.

Dec 03, 2020 08:31 am ET

Thinking about buying stock in Nabriva Therapeutics, Workhorse Group, ReneSola, Riot Blockchain, or Oramed Pharmaceuticals?

NEW YORK, Dec. 3, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NBRV, WKHS, SOL, RIOT, and ORMP.

Nov 30, 2020 08:31 am ET

Thinking about buying stock in Hancock Jaffe, Oramed Pharmaceuticals, Tilray, Hexo Corp, or Arbutus Biopharma?

NEW YORK, Nov. 30, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HJLI, ORMP, TLRY, HEXO, and ABUS.

Nov 14, 2019 06:28 am ET

Oramed Pharmaceuticals to Discuss Positive Phase IIb Data at Investor Event and Conference Call on Monday, November 18th

NEW YORK, Nov. 14, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, will hold an investor event and conference call to review the positive results from the initial cohort of the Phase IIb trial evaluating the efficacy and safety of its lead oral insulin candidate, ORMD-0801.

Nov 12, 2019 06:00 am ET

Oramed Announces Successful Phase IIb Study of Oral Insulin in Type 2 Diabetes

NEW YORK, November 12, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced positive results from the initial cohort of the Phase IIb trial evaluating the efficacy and safety of its lead oral insulin candidate, ORMD-0801, which has the potential to be the first commercial oral insulin capsule for the treatment of diabetes.

Sep 18, 2019 08:38 am ET

Oramed to Present at Ladenburg Thalmann 2019 Healthcare Conference

NEW YORK, Sept. 18, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that the company's Chief Executive Officer, Nadav Kidron, will present and participate in one-on-one meetings at the 2019 Ladenburg Thalmann Healthcare Conference to be held on September 24, 2019 in New York, NY.

Sep 17, 2019 08:40 am ET

Oramed Announces Last Patient Treated in Pivotal Phase IIb Trial of Oral Insulin ORMD-0801

NEW YORK, Sept. 17, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the treatment of the last patient in the primary cohort of the Phase IIb HbA1c trial evaluating Oramed's lead oral insulin candidate, ORMD-0801, which has the potential to be the first commercial oral insulin capsule for the treatment of Type 2 diabetes.

Sep 03, 2019 08:25 am ET

Oramed to Present at Three Upcoming Conferences

NEW YORK, Sept. 3, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that the company will present at three conferences in New York in the first half of September 2019.

Jul 10, 2019 08:40 am ET

Oramed to Present at World Diabetes Congress

NEW YORK, July 10, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that Dr. Miriam Kidron, Chief Scientific Officer of Oramed, will deliver two presentations at the World Diabetes Congress, being held July 15-17, 2019 in Rome, Italy.

Jul 02, 2019 08:25 am ET

Oramed Announces Xiaoming Gao Joins Board of Directors

NEW YORK, July 2, 2019 /PRNewswire/ --Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced that Mr. Xiaoming Gao is joining its board of directors.

May 21, 2019 08:55 am ET

Oramed Completes Patient Recruitment of Phase IIb HbA1c Trial for Oral Insulin Capsule ORMD-0801

NEW YORK, May 21, 2019 /PRNewswire/ --

Apr 29, 2019 08:25 am ET

Oramed to Present at ThinkEquity Conference

NEW YORK, April 29, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will participate in the upcoming ThinkEquity Conference on May 2, 2019 in New York City.

Apr 11, 2019 08:55 am ET

Oramed to Present at 3rd Annual Clinical Trials Summit

NEW YORK, April 11, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will participate in the upcoming 3rd Annual Clinical Trials Summit, taking place on April 29-30, 2019 in Barcelona, Spain.

Apr 04, 2019 08:55 am ET

Oramed Patent Allowed in the U.S. for Oral Exenatide

NEW YORK, April 4, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its U.S. patent for the technology "Methods and Compositions for Oral Administration of Exenatide" has been allowed by the United States Patent and Trademark Office.

Apr 03, 2019 08:55 am ET

Oramed to Present at H.C. Wainwright Global Life Sciences Conference

NEW YORK, April 3, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming H.C. Wainwright Global Life Sciences Conference, taking place April 8-9, 2019 in London.

Mar 28, 2019 08:40 am ET

Oramed Patent Allowed in the U.S. for Key Aspect of Its Oral Delivery Technology

NEW YORK, March 28, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its U.S. patent for the technology "Protease Inhibitor-Containing Compositions, Compositions Comprising Same, and Methods for Producing and using Same" has been allowed by the United States Patent and Trademark Office.

Mar 26, 2019 08:40 am ET

Chinese Regulatory Authority [NMPA] Approves IND Application of Oramed's Oral Insulin Capsules

NEW YORK, March 26, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its Chinese partner, Hefei Tianhui Incubator of Technologies Co., Ltd. ("HTIT"), has reached the significant regulatory milestone of approval of an investigational new drug application ("IND") for two doses of its oral insulin (ORMD-0801). The approval of the IND by the Center For Drug Evaluation of the China National Medical Products Administration ("NMPA",

Feb 06, 2019 07:25 am ET

Oramed to Present at BIO CEO & Investor Conference

NEW YORK, Feb. 6, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming BIO CEO & Investor Conference, taking place February 11-12, 2019 in New York City.

Jan 22, 2019 07:25 am ET

Oramed Initiates Phase I Oral GLP-1 Study Under IND

JERUSALEM, Jan. 22, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has begun recruitment for its Phase 1 pharmacokinetic (PK) study for ORMD-0901, its oral GLP-1 capsule. This is the first study of ORMD-0901 under Oramed's existing FDA Investigational New Drug application (IND). This is a fully-randomized, single-blind, placebo-controlled, crossover study which will evaluate safety in addition to the pharmacokinetics of ORMD

Jan 15, 2019 07:55 am ET

Oramed Pharmaceuticals' CEO Letter to Shareholders

JERUSALEM, Jan. 15, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com)

Jan 09, 2019 07:40 am ET

Oramed Receives Additional $3 Million Milestone Payment from HTIT

JERUSALEM, Jan. 9, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has received a milestone payment of $3 million from Hefei Tianhui Incubator of Technologies Co. Ltd. (HTIT). This milestone is part of a previously-announced license and investment agreement between Oramed and HTIT.

Nov 13, 2018 07:48 am ET

Oramed Completes Over 50% Randomization in Its Pivotal 90-Day Clinical Study

NEW YORK, Nov. 13, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has successfully randomized more than 50% of the expected 285 patients for its 90-day dose-ranging Pivotal Phase 2b clinical study of its oral insulin capsule, ORMD-0801. The double-blind, randomized study for type 2 diabetes was initiated in April 2018 and is designed to generate meaningful data for both efficacy (HbA1c) and safety endpoints.

Nov 05, 2018 07:25 am ET

Oramed to Present at the Tides Europe 2018 Conference

NEW YORK, Nov. 5, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Tides Europe 2018 Conference, EuroPeptides Track, taking place on November 6-9, 2018 in Amsterdam. Dr. Miriam Kidron, Oramed's Chief Scientific Officer, will speak about "Oral Insulin: An Impending Reality?" at the conference on November 7, 2018.

Oct 23, 2018 08:25 am ET

Oramed to Present at Cardiometabolic Health Congress

NEW YORK, Oct. 23, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that a scientific abstract summarizing two recent Phase IIb studies of its orally ingestible insulin capsule, ORMD-0801 in type 1 and type 2 diabetes patients will be presented in a poster at the 13th annual Cardiometabolic Health Congress in Boston, MA.

Oct 04, 2018 08:25 am ET

Oramed Enrolls First Patient in Its Clinical Study for Oral Insulin in the Treatment of NASH

NEW YORK, Oct. 4, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has enrolled the first patient in an exploratory clinical study of its oral insulin capsule, ORMD-0801, in the treatment of nonalcoholic steatohepatitis (NASH).

Sep 17, 2018 10:35 am ET

Oramed Receives FDA Clearance for IND Application for Its Oral GLP-1 Analog Capsule

NEW YORK, Sept. 17, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for human trials of its oral GLP-1 analog capsule ORMD-0901.

Aug 28, 2018 08:25 am ET

Oramed to Present at the H.C. Wainwright Global Investment Conference

NEW YORK, Aug. 28, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming H.C. Wainwright 20th Annual Global Investment Conference, taking place September 4-6, 2018 in New York City. Nadav Kidron, Oramed's CEO, will present a corporate overview at the conference on September 5, 2018.

Jul 24, 2018 08:25 am ET

Oramed Granted Japanese Patent for GLP-1 Analog Capsule

NEW YORK, July 24, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Japanese Intellectual Property Office has publicized its intent to grant Oramed a patent titled, "Methods and Compositions for Oral Administration of Exenatide." The patent covers Oramed's proprietary invention of an oral glucagon-like peptide-1 (GLP-1) analog.

Jul 06, 2018 05:00 pm ET

Oramed Announces Closing of $18.1 Million Registered Direct Offering

NEW YORK, July 6, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the closing of its previously-announced registered direct offering with several healthcare-focused institutional investors. Oramed has sold $18.1 million of shares of common stock and warrants to purchase shares of common stock at a combined price of $6.25 per share and related warrant.

Jul 03, 2018 01:48 am ET

Oramed Announces $18.1 Million Registered Direct Offering

NEW YORK, July 3, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase in a registered direct offering of 2,892,000 shares of its common stock and warrants to purchase up to 2,892,000 shares of its common stock, at a combined purchase price of $6.25 per share and related warrants. The offering is expected to close on or about July 6, 201

Jun 25, 2018 08:25 am ET

Oramed Enrolls First Patient in Its Glucose Clamp Study for Oral Insulin

NEW YORK, June 25, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has enrolled the first patient in its Glucose Clamp Study which will quantify insulin absorption in type 1 diabetes patients treated with its oral insulin capsule, ORMD-0801.

Jun 21, 2018 08:25 am ET

Oramed Initiates Food Effect Study for Its Oral Insulin Capsule ORMD-0801

NEW YORK, June 21, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has initiated a food effect study in the U.S. for its oral insulin capsule ORMD-0801.

Jun 19, 2018 08:25 am ET

Oramed to be Added to Russell Microcap® Index

NEW YORK, June 19, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will be added to the FTSE Russell Microcap® Index effective at the open of market on June 25, 2018, as part of the Russell Indexes annual reconstitution. Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the applicable growth and value style indexes.

Jun 12, 2018 08:25 am ET

Oramed to Present at the American Diabetes Association 78th Scientific Sessions

NEW YORK, June 12, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that three scientific abstracts will be presented as posters at the ADA 78th Scientific Sessions on June 22-25, 2018 in Orlando, Florida. The posters will be presented by Oramed's Chief Scientific Officer, Dr. Miriam Kidron.

May 30, 2018 08:25 am ET

Oramed Patent Allowed in the US for Oral Administration of Proteins

NEW YORK, May 30, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a developer of oral drug delivery systems, announced today that the Company's patent for its invention, titled "Methods and Compositions for Oral Administrations of Proteins," has been allowed by the United States Patent and Trademark Office.

May 09, 2018 06:27 am ET

Frost & Sullivan Publishes Quarterly Update on Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) - Oramed has a sufficient cash balance to fund its clinical development timeline in the near term; severa

TEL AVIV, Israel, May 9, 2018 /CNW/ -- The TASE analysis project was launched in 2016 in order to raise investors' awareness to TASE listed technology and life-science companies and the markets in which these companies operate, thus creating appropriate pricing and increasing the exposure of investors from Israel and abroad. Its goal is to encourage investments in these companies by improving understanding of these industries and companies in the market.

May 09, 2018 06:27 am ET

Frost & Sullivan Publishes Quarterly Update on Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) - Oramed has a sufficient cash balance to fund its clinical development timeline in the near term; severa

TEL AVIV, Israel, May 9, 2018 /PRNewswire/ -- The TASE analysis project was launched in 2016 in order to raise investors' awareness to TASE listed technology and life-science companies and the markets in which these companies operate, thus creating appropriate pricing and increasing the exposure of investors from Israel and abroad. Its goal is to encourage investments in these companies by improving understanding of these industries and companies in the market.

May 07, 2018 08:25 am ET

Oramed to Present at Conferences in May

NEW YORK, May 7, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will present at three conferences over the next two weeks.

Apr 23, 2018 08:25 am ET

Oramed Initiates Its 90-Day Pivotal Dose-Ranging Clinical Study for Oral Insulin

NEW YORK, April 23, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has begun screening patients in its 90-day dose-ranging Pivotal Phase 2b HbA1c clinical study of its oral insulin capsule, ORMD-0801.

Mar 27, 2018 08:25 am ET

Oramed to Present at H.C. Wainwright Annual Global Life Sciences Conference

NEW YORK, March 27, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced it will be featured as a presenting company at the H. C. Wainwright Annual Global Life Sciences Conference. The conference is being held on April 8-10 at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.

Mar 15, 2018 08:48 am ET

Oramed to Present at Oppenheimer's Annual Healthcare Conference

NEW YORK, March 15, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Oppenheimer's 28th Annual Healthcare Conference, being held March 20-21, 2018 at the Westin New York Grand Central in New York City.

Feb 28, 2018 07:25 am ET

Oramed Adds Two New Members to its Scientific Advisory Board

NEW YORK, Feb. 28, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the additions of Drs. Robert Henry and Jane Reusch to its Scientific Advisory Board.

Feb 20, 2018 07:25 am ET

Oramed to Present at the CODHy 6th World Congress on Diabetes, Obesity and Hypertension

JERUSALEM, Feb. 20, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming CODHy Conference, The 6th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension is taking place February 21-22, 2018 in Tel Aviv, Israel.

Feb 06, 2018 07:25 am ET

Oramed to Present at BIO CEO Investor Conference

JERUSALEM, Feb. 6, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming BIO CEO & Investor Conference, taking place February 12-13, 2018 in New York City.

Jan 19, 2018 07:25 am ET

Oramed Pharmaceuticals' CEO Issues Letter to Shareholders

JERUSALEM, Jan. 19, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com)

Nov 14, 2017 08:00 am ET

Oramed Receives Regulatory Approval to Conduct Clinical Study for Treatment of NASH with its Oral Insulin Capsule

JERUSALEM, Nov. 14, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Israel's Ministry of Health has granted the Company approval to initiate an exploratory clinical study of its oral insulin capsule ORMD-0801 in patients with nonalcoholic steatohepatitis (NASH). The proposed three-month treatment study will assess the effectiveness of ORMD-0801 in reducing liver fat content, inflammation and fibrosis in patients with NASH. Oramed plans on

Oct 31, 2017 09:35 am ET

Oramed Granted Broad Composition of Matter Patent in Europe for Oral Proteins

JERUSALEM, Oct. 31, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the European Patent Office has issued to Oramed a notice of intent to grant a patent for broader claims for its invention titled, 'Methods and Compositions for Oral Administration of Proteins'. The claims now extend to cover oral compositions of any protein up to a molecular weight of 100,000 Daltons and uses of the same.

Oct 24, 2017 10:25 am ET

Oramed to Present at the Diabetes Technology Meeting

JERUSALEM, October 24, 2017 /PRNewswire/ --

Oct 17, 2017 09:40 am ET

Endocrinology, Diabetes and Metabolism Journal Publishes Scientific Paper Authored by Oramed Scientists

JERUSALEM, Oct. 17, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the publication of a new paper co-authored by Oramed's Chief Scientific Officer, Dr. Miriam Kidron, Dr. Roy Eldor, Dr. Ehud Arbit and Dr. Yael Greenberg-Shushlav. The paper, "Additive Effect of Oral Insulin and an Oral GLP-1 Agonist on Postprandial Glucose Excursions in a Porcine Model" has been published in the Endocrinology, Diabetes and Metabolism Journal (EDMJ).

Sep 25, 2017 09:55 am ET

Oramed to Present at the Disruptive Growth Showcase Conference

JERUSALEM, Sept. 25, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming 2017 Disruptive Growth Company Showcase NYC Conference, taking place September 27, 2017 in New York City. Nadav Kidron, Oramed's CEO, will present a corporate overview at the conference.

Sep 05, 2017 07:00 am ET

Oramed Announces Successful Meeting with FDA for Oral Insulin

JERUSALEM, Sept. 5, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has successfully concluded its meeting with the U.S. Food and Drug Administration (FDA) regarding ORMD-0801, the Company's novel oral insulin formulation.

Aug 29, 2017 09:50 am ET

Oramed to Present at the Rodman & Renshaw Global Investment Conference

JERUSALEM, August 29, 2017 /PRNewswire/ --

Jul 18, 2017 09:50 am ET

Oramed Appoints Dr. Simon Bruce as Vice President of Medical Affairs

JERUSALEM, July 18, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a developer of oral drug delivery systems, announced today the appointment of Dr. Simon Bruce MD to the newly created position of Vice President of Medical Affairs.

Jul 12, 2017 09:50 am ET

Oramed to Present at BIT'S 5th World Congress of Diabetes on July 13, 2017

JERUSALEM, July 12, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Dr. Miriam Kidron, Oramed's Chief Scientific Officer, will deliver a presentation titled, "Oral Insulin for Diabetes Treatment: Bypassing the Roadblock" at the upcoming BIT'S 5th World Congress of Diabetes-2017 and BIT's 6th World Congress of Endobolism-2017 in Prague, Czech Republic.

Jul 11, 2017 09:50 am ET

Oramed Announces End-of-Phase 2 Meeting with FDA to Initiate Phase 3 Program

JERUSALEM, July 11, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the U.S. Food and Drug Administration (FDA) has agreed to schedule an End-of-Phase II meeting with Oramed for its successfully completed Phase IIb trial of its oral insulin capsule ORMD-0801 in the treatment of type 2 diabetes. The Phase IIb trial met primary and secondary endpoints by indicating a statistically significant lowering of glucose relative to placebo.

Jul 05, 2017 09:50 am ET

Oramed Announces Dual-Listing on Tel Aviv Stock Exchange

JERUSALEM, July 5, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has received approval from the Israel Securities Authority to dual-list its common stock on the Tel Aviv Stock Exchange (TASE). Oramed common stock will commence trading on the TASE on July 12, 2017 under the ticker ORMP. Based on the current market capitalization of the Company, it is expected that Oramed will be included in the TA SME-60 index.

Jun 27, 2017 09:45 am ET

Oramed Granted Japanese Patent for Combination Insulin and GLP-1 Analog Capsule

JERUSALEM, June 27, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Japanese Intellectual Property Office has publicized its intent to grant Oramed a patent titled, "Methods and Compositions for Treating Diabetes" The patent covers Oramed's invention of an oral insulin and glucagon-like peptide-1 (GLP-1) analog combination composition (or therapy).

Jun 06, 2017 09:45 am ET

Oramed to Present at the American Diabetes Association 77th Scientific Sessions

JERUSALEM, June 6, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that a scientific abstract summarizing the recent Phase IIb study of its orally ingestible insulin capsule, ORMD-0801, will be presented in a poster at the ADA 77th Scientific Sessions on June 9-13, 2017 in San Diego.

Jun 05, 2017 11:09 am ET

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Oramed Pharmaceuticals Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

NEW YORK, June 5, 2017 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Oramed Pharmaceuticals Inc. (NASDAQ: ORMP).

May 18, 2017 09:45 am ET

Oramed to Present at Conferences Next Week

JERUSALEM, May 18, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer, Nadav Kidron, will present at three conferences next week in Tel Aviv, Israel.

May 09, 2017 09:45 am ET

Oramed Granted Canadian Patent for GLP-1 Analog Capsule

JERUSALEM, May 9, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Canadian Intellectual Property Office has granted Oramed a patent titled, "Methods and Compositions for Oral Administration of Exenatide". The patent covers Oramed's invention of an oral glucagon-like peptide-1 (GLP-1) analog.

May 02, 2017 09:45 am ET

Oramed Receives Israel Regulatory Approval to Conduct Human Study for New Oral Leptin Capsule

JERUSALEM, May 2, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that based on positive preclinical data, the Company is developing a new drug candidate, a weight loss treatment in the form of an oral leptin capsule. Leptin, also known as the "obesity hormone" is a protein that regulates hunger. According to Grand View Research, the overall obesity market is expected to reach $15.6 billion in 2024.

Apr 20, 2017 09:30 am ET

Oramed Granted European Patent for Combination Oral Insulin and GLP-1 Analog Capsule

JERUSALEM, April 20, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the European Patent Office has granted the Company a patent titled, "Methods and Compositions for Treating Diabetes: Capsules containing oil-based liquid compositions of combined therapeutic agents for treating diabetes." The patent covers Oramed's invention, a combination therapy including both insulin and a GLP-1 analog in a single oral capsule.

Apr 04, 2017 09:45 am ET

Journal of Diabetes Science and Technology Publishes Scientific Paper Authored by Oramed Scientists

JERUSALEM, April 4, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today a new paper co-authored by Oramed's Chief Scientific Officer, Dr. Miriam Kidron, and Dr. Ehud Arbit. The paper, "Oral Insulin Delivery in a Physiologic Context" has been published in the Journal of Diabetes Science and Technology (JDST). JDST is a bi-monthly, peer-reviewed scientific journal published by the Diabetes Technology Society.

Mar 22, 2017 09:45 am ET

Oramed to Present at Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference on March 28, 2017

JERUSALEM, March 22, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Dr. Miriam Kidron, Oramed's Chief Scientific Officer, will deliver a presentation titled, "Oral Insulin for Diabetes Treatment: Bypassing the Roadblock," at the upcoming Cambridge Healthtech Institute's Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference in Cambridge, Massachusetts.

Mar 21, 2017 09:45 am ET

Oramed Appoints Dr. Ronald Law as Chief Strategy Officer

JERUSALEM, March 21, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a developer of oral drug delivery systems, announced today the appointment of Dr. Ronald Law to the newly created position of Chief Strategy Officer.

Feb 07, 2017 08:30 am ET

Oramed to Present at BIO CEO and Investor and Disruptive Growth and Healthcare Conferences

JERUSALEM, Feb. 7, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming BIO CEO & Investor Conference, taking place February 13-14, 2017 in New York City, and the 2017 Disruptive Growth and Healthcare Conference, taking place February 15-16, 2017, also in New York City.

Nov 29, 2016 08:30 am ET

Oramed's ORMD-0901 (Oral GLP-1 Analog) Found Safe and Well Tolerated in Phase Ib Study

JERUSALEM, Nov. 29, 2016 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a developer of oral drug delivery systems, today announced it successfully concluded a Phase Ib study of ORMD-0901, the Company's proprietary oral GLP-1 analog. The Phase Ib study on type 2 diabetic patients showed ORMD-0901 to be safe and well tolerated, having no serious adverse events, adverse events or abnormal laboratory findings during the study. In addition, the active oral GLP-1 arms of the study showed encouraging trending efficacy.

Oct 06, 2016 09:45 am ET

Oramed Receives Additional $4 Million Milestone Payment From HTIT

JERUSALEM, October 6, 2016 /PRNewswire/ --

Sep 19, 2016 10:00 am ET

Oramed to Present at the Aegis Capital Growth Conference

JERUSALEM, September 19, 2016 /PRNewswire/ --

Sep 07, 2016 09:00 am ET

Oramed to Present at the Rodman & Renshaw Global Investment Conference

JERUSALEM, September 7, 2016 /PRNewswire/ --

Aug 02, 2016 10:00 am ET

Oramed Receives Additional $4 Million Milestone Payment From HTIT

JERUSALEM, August 2, 2016 /PRNewswire/ --

Jul 28, 2016 09:15 am ET

Oramed Reports Additional Phase IIb Oral Insulin Study Data Demonstrating Significant Lowering of Glucose Levels vs Placebo

JERUSALEM, July 28, 2016 /PRNewswire/ --

Jul 26, 2016 10:00 am ET

Oramed Appoints Dr. Roy Eldor as Chief Medical Director

JERUSALEM, July 26, 2016 /PRNewswire/ --

Jun 21, 2016 10:05 am ET

Oramed Announces $6.5 Million Milestone Payment from HTIT

JERUSALEM, June 21, 2016 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a developer of oral drug delivery systems, today announced that Hefei Tianhui Incubator of Technologies Co. Ltd. (HTIT) is transferring a $6.5 million milestone payment from the previously-announced license and investment agreement between Oramed and HTIT. The payment follows Oramed's positive top-line results from its Phase IIb U.S. Food and Drug Administration trial designed to evaluate the safety and efficacy of Oramed's oral insulin capsule ORMD-0801 in patients with type 2 diabetes.

Jun 09, 2016 09:15 am ET

You are here

Oramed Pharmaceuticals, Inc. (OQ:ORMP)

Business Focus: Biotechnology & Medical Research